A phase Ib study of the combination of the aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma

Allison Rosenthal; Shaji Kumar; Craig Hofmeister; Jacob Laubach; Ravi Vij; Amylou Dueck; Katherine Gano; A. Keith Stewart

doi:10.1111/bjh.13765

A phase Ib study of the combination of the aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma

Allison Rosenthal, Shaji Kumar, Craig Hofmeister, Jacob Laubach, Ravi Vij, Amylou Dueck, Katherine Gano, A. Keith Stewart

Research output: Contribution to journal › Letter › peer-review

24 Scopus citations

Original language	English
Pages (from-to)	323-325
Number of pages	3
Journal	British Journal of Haematology
Volume	174
Issue number	2
DOIs	https://doi.org/10.1111/bjh.13765
State	Published - Jul 1 2016

Keywords

Alisertib
Aurora kinase
Bortezomib
Multiple myeloma
Relapse

Access to Document

10.1111/bjh.13765

Cite this

@article{cde13092ed33426aa220e442f1325489,

title = "A phase Ib study of the combination of the aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma",

keywords = "Alisertib, Aurora kinase, Bortezomib, Multiple myeloma, Relapse",

author = "Allison Rosenthal and Shaji Kumar and Craig Hofmeister and Jacob Laubach and Ravi Vij and Amylou Dueck and Katherine Gano and Stewart, {A. Keith}",

year = "2016",

month = jul,

day = "1",

doi = "10.1111/bjh.13765",

language = "English",

volume = "174",

pages = "323--325",

journal = "British Journal of Haematology",

issn = "0007-1048",

number = "2",

}

TY - JOUR

T1 - A phase Ib study of the combination of the aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma

AU - Rosenthal, Allison

AU - Kumar, Shaji

AU - Hofmeister, Craig

AU - Laubach, Jacob

AU - Vij, Ravi

AU - Dueck, Amylou

AU - Gano, Katherine

AU - Stewart, A. Keith

PY - 2016/7/1

Y1 - 2016/7/1

KW - Alisertib

KW - Aurora kinase

KW - Bortezomib

KW - Multiple myeloma

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84978077033&partnerID=8YFLogxK

U2 - 10.1111/bjh.13765

DO - 10.1111/bjh.13765

M3 - Letter

C2 - 26403323

AN - SCOPUS:84978077033

SN - 0007-1048

VL - 174

SP - 323

EP - 325

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

A phase Ib study of the combination of the aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma

Keywords

Access to Document

Other files and links

Cite this